A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia

Study Summary

The purpose of this study is to evaluate the safety, tolerability and determine the recommended dose for further clinical evaluation of ELVN-001 in patients with chronic myeloid leukemia with and without T315I mutations in patients who are relapsed, refractory or intolerant to TKIs.

Conditions

Chronic Myeloid Leukemia Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive Cml

Interventions / Drugs

ELVN-001

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment250 participants

Primary Completion—

Lead SponsorEnliven Therapeutics

Data Retrieved2026-04-11 04:12:48.346151+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.